Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
CARNEY SEAN reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Sean Carney received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The award was recorded at a price of $0.00 per share, bringing his direct holdings to 32,209 shares after the grant.
Beta Bionics, Inc. director Adam Lezack reported a mix of stock awards and small planned sales. On May 21, 2026, he received a grant of 16,965 shares of Common Stock at no cost, described as a restricted stock unit award under the company’s 2025 Equity Incentive Plan.
That same day he executed an open-market sale of 1,000 shares at $9.95 per share, followed by a sale of 998 shares at $11.21 per share on May 22, 2026. The filing shows he held 27,399 shares directly after the most recent sale. Both sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
Beta Bionics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of March 23, 2026, there were 44,561,695 shares outstanding, and a quorum of 36,061,048 shares was represented in person or by proxy.
Stockholders elected Class I directors Sean D. Carney and Christy Jones to serve until the 2029 Annual Meeting, with Carney receiving 30,659,060 votes for and Jones 25,865,542 votes for, alongside broker non-votes. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Beta Bionics, Inc. has updated expectations for Mint, its patch insulin pump in development. The company now expects to fully commercialize Mint by the end of the second quarter of 2027, subject to U.S. FDA regulatory clearance of its alternate controller enabled (ACE) insulin pump 510(k) application.
The new timeline reflects the FDA’s initial responses to that application and progress in scaling Mint manufacturing, and the company expects capacity to meet anticipated demand at launch. Mint is expected to offer a 200‑unit insulin reservoir, about three days of wear plus a 12‑hour grace period, smartphone control, waterproof use, and compatibility with leading continuous glucose monitors and Beta Bionics’ FDA‑approved fully adaptive dosing algorithm.
Beta Bionics, Inc. Schedule 13G/A: Eventide Asset Management, LLC and associated filers report beneficial ownership of 5,945,488 shares of Common Stock, representing 13.4% of the outstanding shares as of 03/31/2026. The filing states the shares are held by Eventide funds and separately managed accounts and that the filers disclaim beneficial ownership in accordance with Rule 13d-4.
RTW Investments and Roderick Wong report a 2,000,000-share position in Beta Bionics, Inc. The filing amends prior disclosures and shows the Reporting Persons share voting and dispositive power over 2,000,000 shares, representing 4.5% of the common stock based on 44,561,695 shares outstanding as of March 23, 2026. The shares are held on behalf of the RTW Funds and the statement clarifies ownership and power allocations; signature date is May 15, 2026.
Beta Bionics, Inc. Schedule 13G/A Amendment No. 4 reports holdings by Farallon-related entities and Zone Healthcare Holdings, LLC. Zone Healthcare Holdings, LLC is shown with 2,560,220 shares (5.8%). Several Farallon funds and affiliated persons are shown with positions ranging from 28,440 to 436,671 shares. A group of Farallon individual reporting persons are each reported with 3,607,920 shares (8.1%) in the cover rows incorporated by reference.
The filing lists ownership, voting and dispositive power columns for each reporting person and includes standard disclaimers about beneficial ownership and group status under Section 240.13d-1(c). Signatures show the filing was executed by Hannah E. Dunn on 05/12/2026.
Beta Bionics, Inc. beneficial-ownership disclosure: a Soleus-affiliated group led by Guy Levy reports combined holdings of 4,354,501 shares, equal to 9.8% of common stock. The filing attributes 4,323,714 shares to Soleus Capital Management, L.P. and 1,703,961 shares to Soleus Private Equity Fund II, L.P. The percentage bases on 44,561,695 shares outstanding as of April 16, 2026 per the issuer's Form 10-Q cover. Ownership is shown as shared voting and dispositive power through related Soleus entities; declarants disclaim beneficial ownership except for Section 13(d) purposes.